Biosimilars, which are biologic medical products highly similar to already approved reference products, are becoming increasingly important in cancer treatment. They offer more affordable options once the original product's patent expires. The introduction of biosimilars can significantly reduce treatment costs and increase accessibility. However, the approval and regulation of biosimilars involve complex scientific and regulatory processes to ensure they meet the same standards of safety and efficacy as the original biologics.
